Lourdes Escoda, Tarragona, Spain
Tomás Ripoll-Vera, Palma de Mallorca, Spain
OP01High resolution cryo-em structure of a transthyretin-derived amyloid fibril from a patient with hereditary val30met ATTR amyloidosis
Mathias Schmidt, Ulm, Germany
OP02Defining the cardiac amyloid proteome and its association with patient clinical characteristics and outcomes
Taxiarchis Kourelis, Rochester, MN, USA
OP03Immunogenetic profile of purified pathological plasma cells of patients with light chain amyloidosis
Isabel Cuenca, Madrid, Spain
OP04From protein-protein interaction to protein co-expression networks: a systems biology-based perspective to investigate amyloidosis diseases
Dario Di Silvestre, Milano, Italy
OP05Targeting deubiquitylating enzymes USP14 and UCHL5 in systemic immunoglobulin light chain (al) amyloidosis
Mario Nuvolone, Pavia, Italy
OP06Membrane and soluble b-cell maturation antigen (BCMA) in systemic light-chain amyloidosis
Ping Zhou, Boston, MA, USA
Organ Transplantation in Systemic Amyloidosis
Claudio Rapezzi, Bologna, Italy
Pablo García-Pavía, Madrid, Spain
Heart transplantation in AL amyloidosis
Arnt V. Kristen, Heidelberg, Germany
Heart transplantation in ATTR amyloidosis
Mathew Maurer, NY, USA
Liver transplantation in hereditary ATTR amyloidosis
Bo-Göran Ericzon, Huddinge, Sweden
Kidney transplant in AL amyloidosis and monoclonal immunoglobulin deposition disease: who and when?
Nelson Leung, Rochester, MN, USA
OP 07Skin biopsy in hereditary transthyretin amyloidosis with polyneuropathy in France
Luca Leonardi, Rome, Italy
OP 08Long-term safety and efficacy of patisiran: Global open-label extension 24-month data in patients with hereditary transthyretin-mediated amyloidosis
David Adams, Le Kremlin Bicêtre, France
OP 09Long-term impact of tafamidis in patients with late-onset hereditary transthyretin amyloidosis with stage I polyneuropathy
Roberta Mussinelli, Pavia, Italy
OP 10External validation of the national amyloidosis center score in an international cohort of patients with transthyretin cardiac amyloidosis
Adrián Rivas-Pérez, Madrid, Spain
OP 11Evaluation of patisiran with concomitant or prior use of transthyretin stabilizers in patients with hereditary transthyretin-mediated amyloidosis
H. Lin, Cambridge, MA, USA
OP 12Open-label study of patisiran in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy post-orthotopic liver transplant
Julian Gillmore, London, UK
OP 13High resolution nerve ultrasound as a diagnostic tool for differential diagnosis and progression recognition in TTR-related familial amyloidosis
Natalie Winter, Tübingen, Germany
OP 14Origin of val30met in familial amyloid polyneuropathy (TTR-FAP) in Portugal: a walk through the mutational path
Carolina Lemos, Porto, Portugal
OP 15Liver transplantation and oral drug treatment in the year 2020. Data from the fap world transplant register
Marie Tranäng, Stockholm, Sweden
Multidisciplinary treatment approach in the management of patients with AL Amyloidosis
Giovanni Palladini, Pavia, Italy
Diagnostic pit-falls and risk stratification in AL amyloidosis
Efstathios Kastritis, Athens, Greece
Monoclonal antibody treatment for AL amyloidosis
Ashutosh Wechalekar, London, UK
Novel targets and drugs for AL amyloidosis
Giovanni Palladini, Pavia, Italy
International Kidney MG working Group
(Medusa Meeting Room. Floor -1)
Experts’ Discussion on ASCT in AL amyloidosis: burning questions
Raymond Comenzo, Boston, MA, USA
Vaishali Sanchorawala, Boston, MA, USA
Heather Landau, New York, NY, USA
Hasib Sidiqi, Rochester,MN, USA
Carlos Fernández de Larrea, Barcelona, Spain
Eli Muchtar, Rochester, MN, USA
• Patient selection
• Decreasing transplant-related mortality
• Pretransplant induction
• ASCT in patients with renal function impairment
• Any role for consolidation or maintenance?
• Is it time for CAR-T cell therapy in AL amyloidosis?
Hereditary Transthyretin Amyloidosis
Ole Suhr, Umeå, Sweden
M. Teresa Cibeira, Barcelona, Spain
Multidisciplinary management and quality of life of patients with ATTR polyneuropathy
Teresa Coelho, Porto, Portugal
Potential predictors of response and progression to treatment of hereditary TTR amyloidosis
Violaine Plante-Bordeneuve, Créteil, France
Treatment of hereditary TTR amyloidosis with antisense agents
Carlos Casasnovas, Barcelona, Spain
Rodney H. Falk, Boston, MA, USA
OP16Hepatic expression of mutant transthyretin remodels proteostasis machinery in hereditary ATTR amyloidosis
Richard Giadone, Boston, MA, USA
OP17Diagnostic potential of a novel RT-QPCR-based assay to measure CCND1 MRNA expression levels in bone marrow plasma cells from al amyloidosis patients
Alice Nevone, Pavia, Italy
OP18Machine learning predicts immunoglobulin light chain toxicity through somatic mutations
Maura Garofalo, Bellinzona, Switzerland
OP19Drosophila melanogaster as a model organism for ATTR amyloidosis
Xiaohong Gu, Uppsala, Sweden
OP20Eleven different amyloid types identified in cutaneous amyloidosis by proteomics-based typing
Surendra Dasari, Rochester, MN, USA